Adenomyosis has been linked with lower implantation and live birth rates following in vitro fertilisation, and many clinicians use medical pretreatment before frozen embryo transfer despite ongoing debate about its benefit. The review focuses on this clinical dilemma and the varied approaches used in practice.

This narrative review, guided by a systematic literature search, examines evidence for gonadotropin-releasing hormone agonist (GnRHa) pretreatment alongside alternative medical strategies and different approaches to managing frozen embryo transfer in the context of adenomyosis.

The authors report their assessments by grading each strategy according to study design and the certainty of evidence, and they explicitly separate crude outcome estimates from those adjusted for confounding factors, aiming to clarify the methodological strength behind reported effects.

Why it matters: By grading study design and separating crude from adjusted estimates, the review helps clinicians and laboratory teams understand the strength and limitations of evidence for medical pretreatment before FET in patients with adenomyosis.

This summary was prepared with AI assistance from the source below and is provided for professional information only. Please read the original source before relying on any information. It is not medical advice.